Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Tolerability and Quality of Life in Patients With Multiple Sclerosis Switched to Intramuscular Interferon Beta 1a Autoinjector (Avonex® PenTM)

NCT02076841 is registered in ClinicalTrials.gov with Biogen as lead sponsor.

NCT NCT02076841
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02076841 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Tolerability and Quality of Life in Patients With Multiple Sclerosis Switched to Intramuscular Interferon Beta 1a Autoinjector (Avonex® PenTM)
Lead sponsor
Biogen
Phase
Observational
Overall status
Completed
Start date
July 31, 2013
Completion date
October 31, 2016
Enrollment
40 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

clinical isolated syndrome (cis), multiple sclerosis, relapsing-remitting multiple sclerosis